Javier Sanchez PrietoThe current President and CEO of the airline, formerly Vueling, will be appointed CEO of IVIRMA Global from July, after which he will leave his current position at Iberia.

Thus, as confirmed by the company ServimediaSanchez-Prieto will join world leader in medical services, science, research and technological development in the field of assisted reproduction during the full growth of the group at all levels, with an outstanding medical, scientific and technological investment plan planned for the coming years.

The new CEO of IVIRMA will have to strengthen leadership and expand the success model groups internationally to establish the company as a global reference in assisted reproduction in a time of critical healthcare need. In fact, the WHO itself warned last April of record rates of infertility, noting that “nearly 17.5% of adults experience this problem at some point in their lives” and emphasizing that there is an urgent need to “urgently expand access to quality, affordable help with infertility. for those who need it.”

Precisely in a context in which the need for care and the development of new techniques is essential, the Spanish multinational corporation is a world reference in the field of assisted human reproductive medicine with research centers and centers of excellence in more than 10 countries and which, in addition, manages the largest scientific platform in the medical and scientific specialtywith over 4000 technical publications and collaborations with almost 30 universities.

Currently has more than 120 clinics and 2000 active medical professionals in EuropeUSA and South America, and is an outstanding leader in all markets where it operates.

For their part, the founders of IVIRMA, led by Dr. Antonio Pellicer, who will continue his Same responsibilities as CEOwill continue to lead the medical and scientific divisions, which have played a key role in the company’s success.

The inclusion of Sánchez-Prieto as CEO of IVIRMA comes after KKR acquired the company for nearly €3,000 million in one of the largest private equity transactions in Spain and one of the largest in the healthcare sector in Europe. In this new phase, his ambition, shared with the founding partners of IVIRMA, is to turn the group into a center of excellence on a global level and to promote the Spanish brand in the scientific field from its headquarters in Spain.

It was Sanchez-Prieto who was recognized this week as one of the leaders of the Spanish companies that best protect their brands in the Brand Finance Spain 100 ranking.